Metabolic Disorders
GlobalData’s reports offer expert analysis, insights and opinions to companies in the world’s largest industries. Explore unique market-leading data today and benefit from access to actionable insight within the Metabolic Disorders market. Reports cover market growth forecasts, trends and research, and more.
Browse our full list of Metabolic Disorders market reports here.
- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Sector Analysis
NewSector Analysis NewGlucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in Major Markets, Disease Overview and Drug Forecast to 2033 Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in Major Markets, Disease Overview and Drug Forecast to 2033
$10,995 | May 2024 This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity market through 2033. The use of GLP-1R agonists is expected to quadruple in the next 10 years, at a CAGR of 14.9%. The GLP-1R agonists market across the 7MM was valued at $31.3 billion in 2023, and it is projected to reach $125.3 billion by 2033. At present, GLP-1R...
-
Product Insights
NewProduct Insights NewAmyloidosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update Amyloidosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
$2,500 | April 2024 Amyloidosis Clinical Trial Report Overview A total of 477 amyloidosis clinical trials were conducted as of April 2024. The amyloidosis clinical trial report provides a comprehensive understanding of the amyloidosis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·      North America ·      Europe ·      Asia-Pacific ·      ...
-
Product Insights
NewProduct Insights NewHyperglycemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update Hyperglycemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
$2,500 | March 2024 Hyperglycemia Clinical Trial Report Overview A total of 506 hyperglycemia clinical trials were conducted as of March 2024. The hyperglycemia clinical trial report provides a comprehensive understanding of the hyperglycemia clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       North America ·       Europe ·       Asia-Pacific ·       ...
-
Product Insights
Product Insights Phenylketonuria (PKU) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update Phenylketonuria (PKU) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
$2,500 | February 2024 Phenylketonuria (PKU) Clinical Trial Report Overview A total of 135 PKU clinical trials were conducted as of February 2024. The PKU clinical trial report provides a comprehensive understanding of the Phenylketonuria clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       North America ·       Europe ·       Asia-Pacific...
-
Sector Analysis
Sector Analysis Hyperinsulinemia (HI) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Hyperinsulinemia (HI) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
$3,495 | January 2024 Hyperinsulinemia (HI) Marketed and Pipeline Drugs Report Overview Hyperinsulinemia (HI) is a condition wherein the blood insulin level is higher than the level considered normal in people without diabetes. The pancreas produces insulin that controls blood sugar. Although hyperinsulinemia is not diabetes, the condition is often associated with type 2 diabetes (T2D). Key Mechanisms of Action (Marketed) ·       Receptor Agonist ·       Transporter Inhibitor Key Molecule Types (Marketed) ·       Biologic ·       Small Molecule Key Routes of Administration (Marketed) ·       Injection ·       ...
-
Product Insights
Product Insights Diabetic Foot Ulcers – Drugs In Development, 2023 Diabetic Foot Ulcers – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Diabetic Foot Ulcers - Drugs In Development, 2023’, provides an overview of the Diabetic Foot Ulcers pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Product Insights Amyloidosis – Drugs In Development, 2023 Amyloidosis – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Amyloidosis - Drugs In Development, 2023’, provides an overview of the Amyloidosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Amyloidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Product Insights Diabetic Nephropathy – Drugs In Development, 2023 Diabetic Nephropathy – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Diabetic Nephropathy - Drugs In Development, 2023’, provides an overview of the Diabetic Nephropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Product Insights Diabetic Neuropathy – Drugs In Development, 2023 Diabetic Neuropathy – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Diabetic Neuropathy - Drugs In Development, 2023’, provides an overview of the Diabetic Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Product Insights Hypertriglyceridemia – Drugs In Development, 2023 Hypertriglyceridemia – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Hypertriglyceridemia - Drugs In Development, 2023’, provides an overview of the Hypertriglyceridemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypertriglyceridemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.